Inspira Technologies OXY B.H.N. Ltd. reveals a strategic vision for expansion into liquid biopsy diagnostics, aiming to preserve shareholder value. The proposed acquisition of a liquid biopsy platform will enhance the company’s capabilities in blood-based diagnostics. The platform focuses on analyzing intact circulating tumor cells from blood samples, with initial application in breast cancer. Inspira Technologies aims to accelerate regulatory and commercial advancement of this technology. The company plans to simultaneously support the growth of its respiratory and blood-monitoring platforms with a $15 million equity investment. The transaction is structured to optimize value for existing shareholders while enabling strategic expansion.

Read more at GlobeNewswire: Inspira Outlines Strategic Vision and Transaction Framework